Connecticut General Statutes 20-619a – Biological product prescribing. Prescribing practitioner discussion with patient or representative. Documentation. Patient request to sign for delivery
(a) Prior to prescribing a biological product, as defined in § 20-619, a prescribing practitioner shall discuss with the patient or a representative of the patient the treatment methods, alternatives to and risks associated with the use of such biological product. The prescribing practitioner shall inform the patient that he or she may opt to sign for delivery of the biological product. The prescribing practitioner shall document such discussion in the patient’s medical record not later than twenty-four hours after such discussion has taken place. This section shall not apply to hospital inpatients, emergency care, F.D.A. approved vaccines, blood or blood components.
Terms Used In Connecticut General Statutes 20-619a
- Pharmacy: means a place of business where drugs and devices may be sold at retail and for which a pharmacy license has been issued to an applicant under the provisions of §. See Connecticut General Statutes 20-571
- Prescribing practitioner: means an individual licensed by the state of Connecticut, any other state of the United States, the District of Columbia, the Commonwealth of Puerto Rico or any territory or insular possession subject to the jurisdiction of the United States who is authorized to issue a prescription within the scope of the individual's practice. See Connecticut General Statutes 20-571
- Rescission: The cancellation of budget authority previously provided by Congress. The Impoundment Control Act of 1974 specifies that the President may propose to Congress that funds be rescinded. If both Houses have not approved a rescission proposal (by passing legislation) within 45 days of continuous session, any funds being withheld must be made available for obligation.
(b) The patient or a representative of the patient may make a request of the pharmacy that the patient or representative be present to sign for delivery of the interchangeable biological product. The patient or representative of the patient may rescind such request at any time by notifying the pharmacy of such rescission.